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Testicular cancer is the most common malignant tumor in men aged 15-35 years. Most tumors are of germ cell origin, about half of them are seminomatous, and half are various nonseminomatous germ cell tumors (NSGCT) 4 (1 ). NSGCTs are further classified as embryonal carcinomas, choriocarcinomas, yolk sac tumors, and teratomas. Most of them are mixed germ cell tumors containing several histological components (2 ) .
␣-Fetoprotein (AFP) and human chorionic gonadotropin (hCG) are useful markers for diagnosis and monitoring of testicular cancer. However, there is still a need for new markers to enable earlier detection of relapse and identify high-risk patients before therapy, because treatment of low-stage disease with good prognosis can be limited to surgery to avoid the long-term toxicity of chemotherapy (3 ) . Furthermore, new markers are needed for patients in whom neither hCG nor AFP is increased.
hCG is a glycoprotein hormone composed of an ␣-and a ␤-subunit. The ␣-subunit is common to all glycoprotein hormones, whereas the ␤-subunits differ and convey the biological function of each hormone. hCG is extensively glycosylated, with about 30% of its molecular weight consisting of carbohydrates. In early pregnancy, most of the hCG in circulation is hyperglycosylated (hCG-h), i.e., it contains more complex carbohydrate chains than later in pregnancy (4 ) . hCG-h is secreted by cytotrophoblasts that participate in decidual invasion during implantation, whereas syncytiotrophoblasts secrete regular hCG (5 ) . hCG-h is also produced by trophoblastic tumors (6 -10 ) . hCG-h enhances growth and invasion of choriocarcinoma cell lines (11 ) , and inhibition of hCG expression in JAr choriocarcinoma cells induces their apoptosis (12 ) . The monoclonal antibody B152 against hCG-h inhibits growth of choriocarcinoma cells transplanted into athymic mice (11 ) . hCG-h is thought to be the major form of hCG produced by testicular germ cell tumors and is suggested to be the key to both growth and invasion (6 ), but so far hCG-h has been studied in sera and urine from only a few testicular cancer patients (6 -8 ) and there are no reports on its clinical utility. We studied whether serum hCG from testicular cancer patients is hyperglycosylated and whether measurement of serum hCG-h provides additional clinical information compared with determinations of hCG and the free ␤-subunit of hCG (hCG␤).
Material and Methods

PATIENTS
We analyzed 176 serum samples from 84 testicular cancer patients treated between 1990 and 2003 at Helsinki University Central Hospital. Clinical characteristics (Table 1 and ref (13 ) were retrieved from patient charts in 2006 and were reevaluated by A. Lempiäinen and C. Blomqvist to unify staging based on the International Union Against Cancer classification (14 ) . Three germ cell tumors with an extratesticular primary site were not staged. Routine follow-up consisted of radiographic imaging, serum tumor marker determinations, and clinical examination. Median follow-up time was 1945 days (range 9 -3922 days).
The local ethics committee approved the study. Exemption for obtaining informed consent was provided by the National Supervisory Authority for Welfare and Health. Three pregnancy serum samples were donated by apparently healthy women, who gave verbal informed consent.
SAMPLES
Sixty-seven serum samples were taken before treatment (Table 1) and 20 samples at relapse (4 seminoma and 16 NSGCT patients), and 89 were consecutive follow-up samples taken during or shortly after treatment. Serum samples were stored at ϩ4°C for up to 6 days until assays of hCG and hCG␤. The recoveries of hCG and hCG␤ have previously been found to be stable for 1 week at ϩ4°C (15 ) . Surplus serum was divided into aliquots and stored at Ϫ20°C for 3-14 years before determination of hCG-h and redetermination of hCG.
SERUM DETERMINATIONS
hCG in serum was determined by the AutoDelfia timeresolved immunofluorometric assay (IFMA) (PerkinElmer Wallac) both before and after storage (16 ) . For comparison of various forms, hCG concentrations expressed in international units per liter (IU/L) were converted to molar concentrations (pmol/L) by multiplying by 2.93 (17 ) . The lower limit of detection for hCG is 1.5 pmol/L (0.5 IU/L) and the intraassay CV is Ͻ10% at concentrations between 2.1 pmol/L (0.7 IU/L) and 15 000 pmol/L (5120 IU/L) (18 ) . The upper reference limit for healthy males is 6.2 pmol/L (2.1 IU/L), but because testicular cancer is often associated with testicular malfunction, which may cause a moderate in- (20 ) as capture antibody and MAb 1B2 for detection (21 ) . The assay was calibrated against hCG-h produced by JEG-3 choriocarcinoma cells. The limit of detection was 2 pmol/L and the limit of quantification 5 pmol/L. The interassay CV was Ͻ10% at concentrations above 10 pmol/L (21 ), which was used as a cutoff concentration to define an increased value. In this study, mean CV for duplicate measurements was 6.4%. hCG␤ in serum was determined by an in-house IFMA with MAb 9C11 as capture antibody and MAb 1B2 for detection. The detection limit of the assay was 0.27 pmol/L, the upper reference limit for hCG␤ in serum was 2 pmol/L, and the CV was 2%-10% at concentrations above 3 pmol/L and Ͻ15% at concentrations of 1-3 pmol/L (13, 18 ) . The hCG␤ assay was calibrated against WHO International Reference Reagent (IRR) 99/650 (National Institute of Biological Standards and Control, South Mimms, UK) (22, 23 ) . In one sample with discordant results, hCG was also determined with the Siemens Immulite 2000 (Siemens Medical) and Roche Elecsys total hCG (Roche Diagnostics) assays, according to instructions. These assays recognize hCG, hCG␤, and the core fragment of hCG␤ (24 ) .
The recognition of various forms of hCG in the assays for hCG, hCG␤, and hCG-h was determined by use of the WHO IRR 99/688 for hCG and IRR 99/650 for hCG␤ (23 ) . Because no standard is available for hCG-h, we used hCG-h from the JEG-3 choriocarcinoma cell line medium as a provisional standard for hCG-h.
To study the stability of hCG and hCG␤ during the first week of storage, we determined hCG and hCG␤ at sample arrival; after 1, 3, 6, 24, and 48 h; and after 1 week of storage at ϩ4°C in 3 pregnancy serum samples. To study the effect of freezing, storage, and thawing, we compared serum hCG concentrations determined before and after storage for 3-14 years at Ϫ20°C in 152 serum samples covering a wide range of concentrations.
STATISTICAL ANALYSES
We performed statistical analysis using SPSS version 16.0. The serum concentrations of hCG, hCG-h, and hCG␤ were logarithmically transformed, and we analyzed the association between preoperative marker concentrations and their ratios with tumor type (seminoma vs nonseminoma), location of the primary tumor (gonadal vs extragonadal), stage, tumor size (mm), vascular invasion, and tunica albuginea invasion (Spearman correlation) in all patients and separately in seminoma and NSGCT patients. In all patients, including patients with metastases at diagnosis, progression-free survival time was assessed by Cox regression analysis and by Kaplan-Meyer survival analysis with Mantel-Cox log-rank tests for significance. An event was defined as first detection of recurrence in patients with local disease at diagnosis or in patients in complete remission after chemotherapy for primary metastatic disease. For 2 patients who never achieved remission, the event was defined as the first occurrence of progression. P values below 0.05 were considered significant.
Results
ASSAY SPECIFICITIES
When the recognition of hCG IRR 99/642 was defined as 100%, the recognition of hCG␤ IRR 99/642 was 0.4% in the hCG IFMA. Because the value for the provisional standard of hCG-h was assigned with the hCG IFMA (21 ), the recognition of hCG-h was by definition 100%. In the assay for hCG-h the recognition of hCG IRR 99/642 was 20% and that of hCG␤ IRR 99/642 was 8.7%. The IRRs are purified from pregnancy urine and thus it is not surprising that IRR 99/642 contains 20% hyperglycosylated hCG. The assay for hCG-h also detects hyperglycosylated hCG␤ (hCG␤-h), but the response is about 25% of that for hCG-h. In the assay for hCG␤ the recognition of hCG was 0.4% and that of hCG-h was 2.2%.
STABILITY OF hCG AND hCG␤ DURING STORAGE
The recoveries of hCG and hCG␤ in pregnancy serum remained within 100% (10%) during storage for 1 h to 1 week compared to concentrations determined immediately (see Supplemental Fig. 1 in the Data Supplement that accompanies the online version of this article at http://www.clinchem.org/content/vol58/issue7). Serum hCG concentrations obtained before and after freezing, storage, and thawing correlated strongly with each other (R 2 ϭ 0.98). However, the hCG concentrations were slightly higher after storage (y ϭ 1.036x), probably due to sublimation and sample concentration, and at low concentrations there were 4 outliers (see online Supplemental Fig. 2) . Therefore, to avoid bias caused by storage time, we used hCG concentrations determined after storage when we calculated the proportion of hCG consisting of hCG-h (hCG-h/hCG) (%hCG-h) and calculated %hCG-h for samples with increased concentrations before and after storage.
PREOPERATIVE SERUM CONCENTRATIONS IN NSGCT
In NSGCT patients, the preoperative serum concentrations of both hCG and hCG-h were increased in 28 (74%) and those of hCG␤ in 30 (79%) of the 38 patients. The concentrations of all 3 markers correlated strongly with each other (Fig. 1) . Median %hCG-h was 84% (95% CI 83%-93%, range 38%-130%). The median proportion of hCG␤ to total hCG [hCG␤/(hCG ϩ hCG␤)] was 7% (95% CI 7.1%-13.0%, range 2.9%-33.7%). In NSGCT patients, the concentrations of hCG, hCG-h, and hCG␤ correlated with stage (P values 0.006, 0.005, and 0.003, respectively).
PREOPERATIVE SERUM CONCENTRATIONS IN SEMINOMA
None of the 29 seminoma patients had increased hCG concentrations but 13 (45%) had increased concentrations of hCG␤ (Fig. 1) . One patient with undetectable concentrations of hCG and hCG␤ had an increased concentration of hCG-h (23 pmol/L). When determined with the Immulite assay, the hCG concentration was 200 pmol/L (68 IU/L) and with the Elecsys assay it was 120 pmol/L (41 IU/L). Among patients with increased hCG␤, hCG-h was detectable (37 pmol/L) only in the sample with the highest hCG␤ concentration (450 pmol/L). In all other samples the hCG␤ concentrations were below 50 pmol/L and hCG-h was undetectable. In seminoma patients, hCG␤ correlated with primary tumor size (P ϭ 0.001; r ϭ 0.58).
PROGNOSTIC VALUE
Five of 67 patients relapsed after complete remission and 2 never achieved remission. The 2 who did not achieve remission and 1 other NSGCT patient died of the disease (Table 1 ). All relapses and deaths occurred within 2 years of diagnosis, median time to relapse being 231 (range 187-664) days and median survival time 440 (range 9 -500) days after diagnosis ( Table 1) .
The preoperative serum concentrations of hCG-h, hCG, and hCG␤ correlated with each other and with disease stage (Table 2 ; also see online Supplemental Table 1 ). The concentrations were higher in NSGCT than in seminoma patients. The highest concentrations were observed in a choriocarcinoma patient and in a patient with a choriocarcinoma component in a mixed tumor (see online Supplemental Table 2 ). %hCG-h did not correlate with outcome variables (Table 2) .
In univariate Cox regression analyses, extragonadal primary site and preoperative hCG␤ concentration predicted shorter progression-free survival (Table  3) . In multivariate analysis, only extragonadal primary site remained an independent prognostic factor. Preoperative marker positivity did not predict shorter progression-free survival time in Kaplan-Meyer (Mantel-Cox) analyses (Fig. 2) .
MARKER CONCENTRATIONS AT RELAPSE AND DURING
FOLLOW-UP
In patients with a relapse after complete remission, serum hCG and hCG-h were both increased in 5 of 16 NSGCT and 1 of 4 seminoma patients. Median %hCG-h was 77% (95% CI 57%-112%, range 66%-120%) in NSGCT patients and 60% in the seminoma patient. Additionally, 1 seminoma and 5 NSGCT patients had increased concentrations of hCG␤ with concentrations of hCG and hCG-h that were within reference intervals. All markers remained negative in 6 NSGCT and 2 seminoma patients.
The concentrations of hCG-h, hCG, and hCG␤ followed the disease course in the same way (Fig. 3) . Median %hCG-h was higher [102% (95% CI 100%-122%, range 31%-260%)] during or shortly after treatment, when hCG concentrations were decreasing, than before treatment (83% preoperatively and 77% during relapse; P ϭ 0.004). The sample size was too small for meaningful analyses of false-positive rate.
Discussion
In this study we demonstrated that a major fraction of hCG is hyperglycosylated in testicular cancer patients with increased serum hCG concentrations. Although the proportion in individual patients varied, an increase in serum hCG and hCG-h detected the disease and relapses equally well. Furthermore, the preoperative serum concentrations of hCG-h correlated with known prognostic factors and progression-free survival in the same way as hCG. This finding suggests that measurement of serum hCG-h does not provide additional clinical information compared to that provided by hCG and hCG␤. However, most patients received adjuvant therapy and relapses (n ϭ 5) and diseaserelated deaths (n ϭ 3) were rare. Thus the power to observe statistically significant differences was limited.
hCG-h has been reported to be underestimated by some hCG assays (25 ) . Because most of the hCG in serum of testicular cancer patients is hyperglycosylated, it is important that hCG assays used in the management of testicular cancer detect this form and hCG equally. In the present study, 1 seminoma patient had undetectable concentrations of hCG␤ and hCG but increased concentrations detected with our hCG-h (23 pmol/L) assay and with Immulite (200 pmol/L) and the Elecsys assays (120 pmol/L). The latter 2 assays detect hCG, hCG␤, and fragmented forms of hCG␤ (24 ) . This result suggests that the hCG immunoreactivity of this patient consisted of partially degraded or aberrantly glycosylated hCG or hCG␤. Differences in glycosylation and protein structure have been shown to affect recognition of cancer-derived hCG (25, 26 ) .
In seminomas hCG-h did not have diagnostic value; however, specific assay of hCG␤ was useful in that it was the only form of hCG detected at the time of diagnosis in 45% of the seminoma patients and during relapse in 38% of all patients. Theoretically, total hCG assays detecting hCG␤ and hCG together would miss approximately one third of the marker-positive seminomas, because hCG␤ is often only moderately increased in seminomas and total hCG assays have a higher cutoff concentration, 15 pmol/L, compared to that for the hCG␤ assay, 2 pmol/L (13 ).
One seminoma patient had a high concentration of hCG␤ (450 pmol/L), an hCG concentration within the reference interval, and a moderately increased concentration of hCG-h (37 pmol/L). This result was probably explained by recognition of hyperglycosylated hCG␤ in the assay for hCG-h (21 ) . No hCG-h was detected in 13 patients with undetectable hCG and moderately increased hCG␤ concentrations (3.2-46 pmol/L). This finding can be explained by the low recognition of hCG␤-h in our assay or absence of hCG␤-h. Recognition of hCG␤-h may also explain why %hCG-h exceeded 100% in one fourth of the NS-GCT cases. Most NSGCTs produce hCG␤, and a high concentration of hCG␤-h will increase the results for hCG-h. Another possible explanation is that there were differences in immunoreactivity between the hCG-h calibrator (produced by JEG choriocarcinoma cells) and hCG-h in the samples.
We conclude that most of the hCG in patients with NSGCT is hyperglycosylated, but determination of hCG-h does not appear to provide clinical information additional to that obtained by conventional hCG assays recognizing hCG-h. However, separate measurement of hCG␤ enhances detection of relapse and diagnosis of seminomatous tumors. Because most of hCG in testicular cancers consists of hCG-h, hCG assays used for diagnosis and monitoring of this disease should recognize this form. The bars indicate censored cases for which further patient follow-up information was not available. Note the scale on the y axis (80%-100%). The gray rectangles designate periods of chemotherapy and SCT denotes autologous stem cell transplantation after intensive chemotherapy. 
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